Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Briacell Therap stock logo
BCTX
Briacell Therap
$0.83
+7.1%
$3.03
$0.69
$29.40
$5.60M1.27731,874 shs2.24 million shs
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
$0.86
-0.3%
$0.99
$0.73
$62.00
$4.72M2.58696,499 shs46,743 shs
Longeveron Inc. stock logo
LGVN
Longeveron
$1.47
$1.33
$1.14
$4.88
$21.95M0.21293,350 shs45,337 shs
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$3.50
+2.9%
$3.34
$2.57
$6.88
$21.63M0.629,047 shs2,261 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Briacell Therap stock logo
BCTX
Briacell Therap
-61.88%-73.54%-75.32%-82.81%-94.48%
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
-1.06%-5.09%+7.30%+5.62%-98.53%
Longeveron Inc. stock logo
LGVN
Longeveron
+3.52%-11.45%+13.08%+4.26%-62.78%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
+0.59%+3.01%-1.13%+24.36%-39.25%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Briacell Therap stock logo
BCTX
Briacell Therap
1.8721 of 5 stars
3.52.00.00.02.40.00.6
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
2.1183 of 5 stars
3.34.00.00.02.00.00.6
Longeveron Inc. stock logo
LGVN
Longeveron
3.1512 of 5 stars
3.64.00.00.02.71.70.6
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
1.4542 of 5 stars
0.04.00.00.03.31.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Briacell Therap stock logo
BCTX
Briacell Therap
3.00
Buy$32.003,778.79% Upside
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
2.50
Moderate Buy$25.002,793.52% Upside
Longeveron Inc. stock logo
LGVN
Longeveron
3.25
Buy$8.67489.57% Upside
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest CNSP, NAII, BCTX, and LGVN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/22/2025
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
Alliance Global Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
4/22/2025
Briacell Therap stock logo
BCTX
Briacell Therap
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Briacell Therap stock logo
BCTX
Briacell Therap
N/AN/AN/AN/A($2.20) per shareN/A
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
N/AN/AN/AN/A$5.37 per shareN/A
Longeveron Inc. stock logo
LGVN
Longeveron
$2.39M9.18N/AN/A$1.47 per share1.00
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$113.80M0.19N/AN/A$13.32 per share0.26
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Briacell Therap stock logo
BCTX
Briacell Therap
-$4.79M-$8.32N/AN/AN/AN/A-479.97%-182.26%N/A
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
-$14.86M-$3,748.50N/AN/AN/A-385.41%-193.20%8/13/2025 (Estimated)
Longeveron Inc. stock logo
LGVN
Longeveron
-$15.97M-$6.28N/AN/AN/A-760.72%-85.07%-70.74%8/13/2025 (Estimated)
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-$7.22M-$1.39N/AN/A-6.56%-10.34%-5.19%9/25/2025 (Estimated)

Latest CNSP, NAII, BCTX, and LGVN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Longeveron Inc. stock logo
LGVN
Longeveron
-$0.35N/AN/AN/A$0.41 millionN/A
6/13/2025Q3 2025
Briacell Therap stock logo
BCTX
Briacell Therap
-$1.76-$1.64+$0.12-$1.64N/AN/A
5/15/2025Q1 2025
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
N/A-$1.58N/A-$1.58N/AN/A
5/14/2025Q3 2025
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/A-$0.37N/A-$0.37N/A$28.77 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Briacell Therap stock logo
BCTX
Briacell Therap
N/AN/AN/AN/AN/A
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
N/AN/AN/AN/AN/A
Longeveron Inc. stock logo
LGVN
Longeveron
N/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Briacell Therap stock logo
BCTX
Briacell Therap
N/A
3.41
3.41
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
N/A
4.94
4.94
Longeveron Inc. stock logo
LGVN
Longeveron
N/A
5.61
5.61
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.11
2.51
1.35

Institutional Ownership

CompanyInstitutional Ownership
Briacell Therap stock logo
BCTX
Briacell Therap
15.42%
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
14.02%
Longeveron Inc. stock logo
LGVN
Longeveron
10.01%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
32.40%

Insider Ownership

CompanyInsider Ownership
Briacell Therap stock logo
BCTX
Briacell Therap
5.73%
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
0.07%
Longeveron Inc. stock logo
LGVN
Longeveron
11.20%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
20.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Briacell Therap stock logo
BCTX
Briacell Therap
86.78 million6.39 millionOptionable
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
55.46 million5.46 millionNot Optionable
Longeveron Inc. stock logo
LGVN
Longeveron
2014.93 million13.26 millionNot Optionable
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
2906.18 million4.89 millionNot Optionable

Recent News About These Companies

Natural Alternatives International, Inc. Announces 2025 Q2 and YTD Results
CarnoSyn Brands announces new U.S. distribution pact with B&D Nutritional
(NAII) Trading Advice

New MarketBeat Followers Over Time

Media Sentiment Over Time

Briacell Therap stock logo

Briacell Therap NASDAQ:BCTX

$0.82 +0.06 (+7.14%)
As of 12:30 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

CNS Pharmaceuticals stock logo

CNS Pharmaceuticals NASDAQ:CNSP

$0.86 0.00 (-0.25%)
As of 12:30 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.

Longeveron stock logo

Longeveron NASDAQ:LGVN

$1.47 0.00 (0.00%)
As of 12:31 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

Natural Alternatives International stock logo

Natural Alternatives International NASDAQ:NAII

$3.50 +0.10 (+2.94%)
As of 12:30 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States, Europe, Australia, Asia, Mexico, and Canada. The company operates in two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. The company also provides strategic partnering services, such as customized product formulation, clinical study design and support, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management, packaging and delivery system design, regulatory review, and international product registration assistance. In addition, it sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. The company was founded in 1980 and is headquartered in Carlsbad, California.